Biofrontera Inc. Announces Participation in Two Dermatology Conferences in January
January 10 2022 - 8:45AM
Biofrontera
Inc. (Nasdaq: BFRI)
(the “Company”), a biopharmaceutical company specializing in the
commercialization of dermatological products, announced today that
it plans to participate in the following two dermatology
conferences in January:
- 2022 Winter Clinical Dermatology
Conference at the Grand Hyatt in Kauai, January 14-19, 2022
- Maui Derm for Dermatologists 2022
at the Grand Wailea, January 24-28, 2022
At each conference, clinical data for
Biofrontera’s two FDA-approved products, Ameluz® and Xepi®, will be
presented. The presentations will provide an overview of multiple
recent studies involving photodynamic therapy (PDT) used in
combination with the flagship product Ameluz® (Ameluz-PDT), such as
the recently published pharmacokinetic data, and findings from
investigator-initiated trials (IIT). The presentations will be
complemented by continuing medical education (CME) sessions on
actinic keratosis (AK), PDT and the recent FDA-approval of the new
PDT-lamp RhodoLED XL.
In addition, the Company will host an expert
advisory board meeting (Ad Board) with nine dermatologists at the
2022 Winter Clinical Dermatology Conference. The goal of the Ad
Board is to gain insight and guidance from experts on key clinical
and scientific messaging that address unmet needs as well as
approaches to best communicate clinical data findings, including
Biofrontera’s recent regulatory approval of the RhodoLED XL
lamp.
Erica Monaco, Chief Executive Officer of
Biofrontera Inc., commented, “We are extremely pleased with the
growing body of high-quality scientific data for each product in
our portfolio. The published clinical data highlight advantages of
using Ameluz-PDT in the treatment of AK, a common precursor to
non-melanoma skin cancer. The IITs also represent confidence and
interest within the dermatology community, strengthening the
competitive positioning of Ameluz-PDT.”
About Biofrontera Inc.
Biofrontera Inc. is a U.S.-based
biopharmaceutical company commercializing a portfolio of
pharmaceutical products for the treatment of dermatological
conditions with a focus on photodynamic therapy (PDT) and topical
antibiotics. The Company’s licensed products are used for the
treatment of actinic keratoses, which are pre-cancerous skin
lesions, as well as impetigo, a bacterial skin infection. For more
information, visit www.biofrontera-us.com.
Forward-Looking Statements
Certain statements in this press release may
constitute "forward-looking statements" within the meaning of the
United States Private Securities Litigation Reform Act of 1995, as
amended to date. These statements include, but are not limited to,
statements relating to the expected trading commencement and
closing dates. We have based these forward-looking statements on
our current expectations and projections about future events,
nevertheless, actual results or events could differ materially from
the plans, intentions and expectations disclosed in, or implied by,
the forward-looking statements we make. These risks and
uncertainties, many of which are beyond our control, including, but
not limited to, the impact of extraordinary external events, such
as the current COVID-19 pandemic; any changes in the Company’s
relationship with the Licensor; the outcome of the Company’s
litigation with DUSA Pharmaceuticals, Inc., including the trial
scheduled to begin at the end of November; the Company’s ability to
achieve and sustain profitability; whether the current disruptions
in the supply chain will impact the Company’s ability to obtain and
distribute its licensed products; changes in the practices of
healthcare providers, including any changes to the coverage,
reimbursement and pricing for procedures using the Company’s
licensed products; the uncertainties inherent in the initiation and
conduct of clinical trials; availability and timing of data from
clinical trials; whether results of early clinical trials or trials
in different disease indications will be indicative of the results
of ongoing or future trials; whether results of the studies
described above will be indicative of results for any future
clinical trials and studies of Ameluz® in combination with
BF-RhodoLED®; uncertainties associated with regulatory review of
clinical trials and applications for marketing approvals; whether
the market opportunity for Ameluz® in combination with BF-RhodoLED®
is consistent with the Company’s expectations; whether the Company
will be able to successfully transition to a public company
operating independently of Biofrontera AG; the Company’s ability to
retain and hire key personnel; the sufficiency of cash resources
and need for additional financing and other factors that may be
disclosed in the Company’s filings with the SEC, which can be
obtained on the SEC website at www.sec.gov. Readers are cautioned
not to place undue reliance on the forward-looking statements,
which speak only as of the date on which they are made and reflect
management's current estimates, projections, expectations and
beliefs. The company does not plan to update any such
forward-looking statements and expressly disclaims any duty to
update the information contained in this press release except as
required by law.
Contacts
Biofrontera Inc.Pamela Keck+1
781 486 1539us-ir@biofrontera.com
LHA Investor RelationsTirth T.
Patel+1 212 201 6614tpatel@lhai.com
# # #
Biofrontera (NASDAQ:BFRI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Biofrontera (NASDAQ:BFRI)
Historical Stock Chart
From Apr 2023 to Apr 2024